| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
As a lactosylceramide, Lc2Cer(d18:1, 22:0) targets components of the cell membrane and is involved in cellular signaling pathways. It can interact with various receptors and signaling molecules in lipid rafts, influencing processes such as cell differentiation, proliferation, and apoptosis. It has been used for renal cortical epithelial cell research, indicating a potential role in kidney biology.
|
|---|---|
| ln Vitro |
Lc2Cer(d18:1, 22:0) is an endogenous bioactive sphingolipid. C22-ceramide reduces the propensity of C16-ceramide channel formation in isolated rat liver mitochondria and in liposomes. It may also be involved in modulating membrane properties and signaling cascades. Its biological activity is often studied in the context of lipid metabolism and cell signaling pathways.
|
| ln Vivo |
No in vivo activity data is specifically provided in the search results. However, given its role as a bioactive lipid, it is likely involved in various physiological processes. C22-Ceramide is an endogenous lipid that can be studied in animal models to understand its effects on metabolism, inflammation, and cell signaling. Further research is needed to define its in vivo activity profiles.
|
| Enzyme Assay |
For in vitro binding assays, surface plasmon resonance (SPR) or liposome-based binding assays can be used to study interactions between Lc2Cer(d18:1, 22:0) and its binding partners (e.g., proteins, other lipids). The compound can be incorporated into model membranes to study its biophysical properties. The binding affinity (Kd) to specific proteins or receptors is determined by titration experiments.
|
| Cell Assay |
For in vitro cell assays, renal cortical epithelial cells are treated with Lc2Cer(d18:1, 22:0). Cells are cultured in appropriate media, and the lactosylceramide is added at varying concentrations. Following treatment, cells are harvested, and lysates are analyzed by Western blot to assess changes in protein expression and signaling pathways. Cell viability may be assessed using assays such as MTT or CellTiter-Glo. Changes in membrane properties or lipid raft dynamics can also be studied.
|
| Animal Protocol |
For in vivo animal experiments, Lc2Cer(d18:1, 22:0) can be administered to mice or rats, typically via intravenous (IV) or intraperitoneal (IP) injection. The compound can be formulated in a vehicle such as 10% DMSO, 40% PEG300, 5% Tween 80, and 45% saline. Blood and tissue samples (e.g., kidney, liver) are collected at predetermined time points. Lipid extracts are prepared, and levels of Lc2Cer are measured by LC-MS/MS. Tissue histology and markers of lipid metabolism or inflammation may be assessed.
|
| ADME/Pharmacokinetics |
No dedicated PK data is available for Lc2Cer(d18:1, 22:0) in the search results. As an endogenous lipid, its pharmacokinetics involves absorption, distribution, metabolism, and excretion pathways specific to sphingolipids. It is likely incorporated into cell membranes and lipoproteins. Its half-life (t1/2) and volume of distribution (Vd) would be determined by its lipid nature and would require specific studies using radiolabeled or isotopically labeled compound.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is available. As an endogenous bioactive lipid, it is generally considered non-toxic at physiological concentrations, but high doses may have cytotoxic or immunomodulatory effects. In animal studies, toxicity would be evaluated by monitoring body weight, clinical signs, and serum chemistry (ALT, AST, BUN, creatinine). Histopathology of major organs would be performed to assess any adverse effects.
|
| References | |
| Additional Infomation |
This compound has the molecular formula C52H99NO13 and a molecular weight of 946.34 g/mol. It appears as a white to off-white solid powder. The product is for research use only and is available as a biochemical assay reagent. Storage: powder at -20degC for 3 years; in solvent at -80degC for 6 months. It is soluble in DMSO, ethanol, and DMF. It is also known as LacCer(d18:1/22:0).
|
| Molecular Formula |
C52H99NO13
|
|---|---|
| Molecular Weight |
946.34
|
| CAS # |
111142-68-8
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0567 mL | 5.2835 mL | 10.5670 mL | |
| 5 mM | 0.2113 mL | 1.0567 mL | 2.1134 mL | |
| 10 mM | 0.1057 mL | 0.5284 mL | 1.0567 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
